Related Experiment Video
Updated: May 29, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Spotlight on lenalidomide in relapsed or refractory multiple myeloma
Lesley J Scott1, Katherine A Lyseng-Williamson
1Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|September 28, 2011
Summary
Lenalidomide plus dexamethasone is an effective treatment for multiple myeloma patients. This combination therapy offers cost-effective benefits and improves outcomes in relapsed or refractory cases.
Area of Science:
- Hematology
- Oncology
- Pharmacoeconomics
Background:
- Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
- Lenalidomide, an immunomodulatory drug, exhibits antiproliferative and anti-angiogenic properties.
- Current treatments aim to control disease progression and improve patient survival.
Purpose of the Study:
- To evaluate the efficacy and safety of lenalidomide plus dexamethasone in multiple myeloma.
- To assess the cost-effectiveness of this combination therapy from healthcare payer perspectives.
- To analyze the impact on progression-free survival and overall survival.
Main Methods:
- Phase III clinical trials (MM-009 and MM-010) involving patients with relapsed or refractory multiple myeloma.
- Pharmacoeconomic analyses comparing lenalidomide plus dexamethasone with dexamethasone alone or bortezomib.
- Statistical analysis of efficacy endpoints including overall response rate and time to progression.
Main Results:
- Lenalidomide plus dexamethasone demonstrated efficacy and a manageable safety profile.
- Pharmacoeconomic analyses indicated cost-effectiveness in the UK, Scotland, Norway, and Sweden.
- Significant improvements in median time to progression, overall response rates, and overall survival were observed.
Conclusions:
- Combination therapy with lenalidomide and dexamethasone is a valuable treatment option for relapsed or refractory multiple myeloma.
- The treatment offers a favorable cost-effectiveness profile for healthcare systems.
- This regimen improves key clinical outcomes for patients with multiple myeloma.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...